Antonio Di Cristofano is a Professor of Developmental and Molecular Biology at the Albert Einstein College of Medicine (Bronx, NY). His general area of expertise is Cancer Biology and Signaling. He received his PhD in Cellular and Molecular Genetics from the University of Naples, Italy, in 1996, before moving to Memorial Sloan Kettering Cancer Center in New York for postdoctoral training.
In 2001 he was recruited by the Fox Chase Cancer Center in Philadelphia, where he was awarded tenure in 2008. In the same year he moved back to New York, recruited as an Associate Professor by the Albert Einstein College of Medicine. He was promoted to Professor in 2013, and awarded tenure in 2017.
Dr. Di Cristofano’s interests span basic and preclinical thyroid cancer research. His NIH-funded work has contributed to the elucidation of the key role played by the PI3K/mTOR signaling cascade in the pathogenesis of follicular and anaplastic thyroid cancer and to the development of novel, rationally designed combinatorial therapeutic approaches for anaplastic thyroid cancer.
His current research focuses on the identification of the genetic and signaling alterations associated in vivo with thyroid cancer progression and resistance to targeted therapy, and on the development of pro-apoptotic therapies for advanced thyroid cancer.
Dr. Di Cristofano is a member of the NIH Tumor Cell Biology [TCB] Study Section and serves as an Associate Editor of Endocrine-Related Cancer.
A member of the American Thyroid Association since 2008, Dr. Di Cristofano was the recipient of the 2012 ATA Van Meter Award.
The lecture video：0
Symposium 8 Anaplastic and Poorly Differentiated Thyroid Cancers
|Speaker||Review of Animal Models|